Drug Profile
YD 308
Alternative Names: YD-308Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator YD Global Life Science
- Class Antidementias
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Dementia
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Alzheimer's disease in South Korea (unspecified route)
- 04 Sep 2023 Discontinued - Preclinical for Dementia in South Korea (unspecified route)
- 28 Nov 2018 No recent reports of development identified for preclinical development in Alzheimer's-disease in South Korea